Immunotherapy in ovarian cancer
Immunotherapy aims to develop combination approaches that simultaneously augment immunity while preventing local immune suppression. Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for patients with ov...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Krishnan, Venkatesh [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
16 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Breastfeeding, Polyunsaturated Fatty Acid Levels in Colostrum and Child Intelligence Quotient at Age 5-6 Years - Bernard, Jonathan Y. ELSEVIER, 2017, Orlando, Fla |
|---|---|
| Übergeordnetes Werk: |
volume:41 ; year:2017 ; number:1 ; pages:48-63 ; extent:16 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.currproblcancer.2016.11.003 |
|---|
| Katalog-ID: |
ELV040281752 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV040281752 | ||
| 003 | DE-627 | ||
| 005 | 20230625231412.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.currproblcancer.2016.11.003 |2 doi | |
| 028 | 5 | 2 | |a GBVA2017003000025.pica |
| 035 | |a (DE-627)ELV040281752 | ||
| 035 | |a (ELSEVIER)S0147-0272(16)30172-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 150 |q VZ |
| 084 | |a LING |q DE-30 |2 fid | ||
| 084 | |a 77.00 |2 bkl | ||
| 100 | 1 | |a Krishnan, Venkatesh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunotherapy in ovarian cancer |
| 264 | 1 | |c 2017transfer abstract | |
| 300 | |a 16 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Immunotherapy aims to develop combination approaches that simultaneously augment immunity while preventing local immune suppression. Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for patients with ovarian cancer are inadequate. Advances in immunotherapy offer a promising frontier for treating ovarian tumors. Multiple immunotherapeutic modalities are currently developed and tested in clinical trials. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor–modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery. | ||
| 520 | |a Immunotherapy aims to develop combination approaches that simultaneously augment immunity while preventing local immune suppression. Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for patients with ovarian cancer are inadequate. Advances in immunotherapy offer a promising frontier for treating ovarian tumors. Multiple immunotherapeutic modalities are currently developed and tested in clinical trials. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor–modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery. | ||
| 650 | 7 | |a ovarian cancer |2 Elsevier | |
| 650 | 7 | |a Immunotherapy |2 Elsevier | |
| 700 | 1 | |a Berek, Jonathan S. |4 oth | |
| 700 | 1 | |a Dorigo, Oliver |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Mosby |a Bernard, Jonathan Y. ELSEVIER |t Breastfeeding, Polyunsaturated Fatty Acid Levels in Colostrum and Child Intelligence Quotient at Age 5-6 Years |d 2017 |g Orlando, Fla |w (DE-627)ELV020620217 |
| 773 | 1 | 8 | |g volume:41 |g year:2017 |g number:1 |g pages:48-63 |g extent:16 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.currproblcancer.2016.11.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a FID-LING | ||
| 936 | b | k | |a 77.00 |j Psychologie: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 41 |j 2017 |e 1 |h 48-63 |g 16 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
v k vk |
|---|---|
| matchkey_str |
krishnanvenkateshberekjonathansdorigooli:2017----:muohrpioai |
| hierarchy_sort_str |
2017transfer abstract |
| bklnumber |
77.00 |
| publishDate |
2017 |
| allfields |
10.1016/j.currproblcancer.2016.11.003 doi GBVA2017003000025.pica (DE-627)ELV040281752 (ELSEVIER)S0147-0272(16)30172-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 150 VZ LING DE-30 fid 77.00 bkl Krishnan, Venkatesh verfasserin aut Immunotherapy in ovarian cancer 2017transfer abstract 16 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Immunotherapy aims to develop combination approaches that simultaneously augment immunity while preventing local immune suppression. Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for patients with ovarian cancer are inadequate. Advances in immunotherapy offer a promising frontier for treating ovarian tumors. Multiple immunotherapeutic modalities are currently developed and tested in clinical trials. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor–modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery. Immunotherapy aims to develop combination approaches that simultaneously augment immunity while preventing local immune suppression. Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for patients with ovarian cancer are inadequate. Advances in immunotherapy offer a promising frontier for treating ovarian tumors. Multiple immunotherapeutic modalities are currently developed and tested in clinical trials. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor–modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery. ovarian cancer Elsevier Immunotherapy Elsevier Berek, Jonathan S. oth Dorigo, Oliver oth Enthalten in Mosby Bernard, Jonathan Y. ELSEVIER Breastfeeding, Polyunsaturated Fatty Acid Levels in Colostrum and Child Intelligence Quotient at Age 5-6 Years 2017 Orlando, Fla (DE-627)ELV020620217 volume:41 year:2017 number:1 pages:48-63 extent:16 https://doi.org/10.1016/j.currproblcancer.2016.11.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-LING 77.00 Psychologie: Allgemeines VZ AR 41 2017 1 48-63 16 045F 610 |
| spelling |
10.1016/j.currproblcancer.2016.11.003 doi GBVA2017003000025.pica (DE-627)ELV040281752 (ELSEVIER)S0147-0272(16)30172-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 150 VZ LING DE-30 fid 77.00 bkl Krishnan, Venkatesh verfasserin aut Immunotherapy in ovarian cancer 2017transfer abstract 16 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Immunotherapy aims to develop combination approaches that simultaneously augment immunity while preventing local immune suppression. Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for patients with ovarian cancer are inadequate. Advances in immunotherapy offer a promising frontier for treating ovarian tumors. Multiple immunotherapeutic modalities are currently developed and tested in clinical trials. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor–modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery. Immunotherapy aims to develop combination approaches that simultaneously augment immunity while preventing local immune suppression. Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for patients with ovarian cancer are inadequate. Advances in immunotherapy offer a promising frontier for treating ovarian tumors. Multiple immunotherapeutic modalities are currently developed and tested in clinical trials. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor–modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery. ovarian cancer Elsevier Immunotherapy Elsevier Berek, Jonathan S. oth Dorigo, Oliver oth Enthalten in Mosby Bernard, Jonathan Y. ELSEVIER Breastfeeding, Polyunsaturated Fatty Acid Levels in Colostrum and Child Intelligence Quotient at Age 5-6 Years 2017 Orlando, Fla (DE-627)ELV020620217 volume:41 year:2017 number:1 pages:48-63 extent:16 https://doi.org/10.1016/j.currproblcancer.2016.11.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-LING 77.00 Psychologie: Allgemeines VZ AR 41 2017 1 48-63 16 045F 610 |
| allfields_unstemmed |
10.1016/j.currproblcancer.2016.11.003 doi GBVA2017003000025.pica (DE-627)ELV040281752 (ELSEVIER)S0147-0272(16)30172-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 150 VZ LING DE-30 fid 77.00 bkl Krishnan, Venkatesh verfasserin aut Immunotherapy in ovarian cancer 2017transfer abstract 16 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Immunotherapy aims to develop combination approaches that simultaneously augment immunity while preventing local immune suppression. Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for patients with ovarian cancer are inadequate. Advances in immunotherapy offer a promising frontier for treating ovarian tumors. Multiple immunotherapeutic modalities are currently developed and tested in clinical trials. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor–modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery. Immunotherapy aims to develop combination approaches that simultaneously augment immunity while preventing local immune suppression. Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for patients with ovarian cancer are inadequate. Advances in immunotherapy offer a promising frontier for treating ovarian tumors. Multiple immunotherapeutic modalities are currently developed and tested in clinical trials. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor–modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery. ovarian cancer Elsevier Immunotherapy Elsevier Berek, Jonathan S. oth Dorigo, Oliver oth Enthalten in Mosby Bernard, Jonathan Y. ELSEVIER Breastfeeding, Polyunsaturated Fatty Acid Levels in Colostrum and Child Intelligence Quotient at Age 5-6 Years 2017 Orlando, Fla (DE-627)ELV020620217 volume:41 year:2017 number:1 pages:48-63 extent:16 https://doi.org/10.1016/j.currproblcancer.2016.11.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-LING 77.00 Psychologie: Allgemeines VZ AR 41 2017 1 48-63 16 045F 610 |
| allfieldsGer |
10.1016/j.currproblcancer.2016.11.003 doi GBVA2017003000025.pica (DE-627)ELV040281752 (ELSEVIER)S0147-0272(16)30172-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 150 VZ LING DE-30 fid 77.00 bkl Krishnan, Venkatesh verfasserin aut Immunotherapy in ovarian cancer 2017transfer abstract 16 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Immunotherapy aims to develop combination approaches that simultaneously augment immunity while preventing local immune suppression. Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for patients with ovarian cancer are inadequate. Advances in immunotherapy offer a promising frontier for treating ovarian tumors. Multiple immunotherapeutic modalities are currently developed and tested in clinical trials. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor–modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery. Immunotherapy aims to develop combination approaches that simultaneously augment immunity while preventing local immune suppression. Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for patients with ovarian cancer are inadequate. Advances in immunotherapy offer a promising frontier for treating ovarian tumors. Multiple immunotherapeutic modalities are currently developed and tested in clinical trials. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor–modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery. ovarian cancer Elsevier Immunotherapy Elsevier Berek, Jonathan S. oth Dorigo, Oliver oth Enthalten in Mosby Bernard, Jonathan Y. ELSEVIER Breastfeeding, Polyunsaturated Fatty Acid Levels in Colostrum and Child Intelligence Quotient at Age 5-6 Years 2017 Orlando, Fla (DE-627)ELV020620217 volume:41 year:2017 number:1 pages:48-63 extent:16 https://doi.org/10.1016/j.currproblcancer.2016.11.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-LING 77.00 Psychologie: Allgemeines VZ AR 41 2017 1 48-63 16 045F 610 |
| allfieldsSound |
10.1016/j.currproblcancer.2016.11.003 doi GBVA2017003000025.pica (DE-627)ELV040281752 (ELSEVIER)S0147-0272(16)30172-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 150 VZ LING DE-30 fid 77.00 bkl Krishnan, Venkatesh verfasserin aut Immunotherapy in ovarian cancer 2017transfer abstract 16 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Immunotherapy aims to develop combination approaches that simultaneously augment immunity while preventing local immune suppression. Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for patients with ovarian cancer are inadequate. Advances in immunotherapy offer a promising frontier for treating ovarian tumors. Multiple immunotherapeutic modalities are currently developed and tested in clinical trials. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor–modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery. Immunotherapy aims to develop combination approaches that simultaneously augment immunity while preventing local immune suppression. Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for patients with ovarian cancer are inadequate. Advances in immunotherapy offer a promising frontier for treating ovarian tumors. Multiple immunotherapeutic modalities are currently developed and tested in clinical trials. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor–modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery. ovarian cancer Elsevier Immunotherapy Elsevier Berek, Jonathan S. oth Dorigo, Oliver oth Enthalten in Mosby Bernard, Jonathan Y. ELSEVIER Breastfeeding, Polyunsaturated Fatty Acid Levels in Colostrum and Child Intelligence Quotient at Age 5-6 Years 2017 Orlando, Fla (DE-627)ELV020620217 volume:41 year:2017 number:1 pages:48-63 extent:16 https://doi.org/10.1016/j.currproblcancer.2016.11.003 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-LING 77.00 Psychologie: Allgemeines VZ AR 41 2017 1 48-63 16 045F 610 |
| language |
English |
| source |
Enthalten in Breastfeeding, Polyunsaturated Fatty Acid Levels in Colostrum and Child Intelligence Quotient at Age 5-6 Years Orlando, Fla volume:41 year:2017 number:1 pages:48-63 extent:16 |
| sourceStr |
Enthalten in Breastfeeding, Polyunsaturated Fatty Acid Levels in Colostrum and Child Intelligence Quotient at Age 5-6 Years Orlando, Fla volume:41 year:2017 number:1 pages:48-63 extent:16 |
| format_phy_str_mv |
Article |
| bklname |
Psychologie: Allgemeines |
| institution |
findex.gbv.de |
| topic_facet |
ovarian cancer Immunotherapy |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Breastfeeding, Polyunsaturated Fatty Acid Levels in Colostrum and Child Intelligence Quotient at Age 5-6 Years |
| authorswithroles_txt_mv |
Krishnan, Venkatesh @@aut@@ Berek, Jonathan S. @@oth@@ Dorigo, Oliver @@oth@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
ELV020620217 |
| dewey-sort |
3610 |
| id |
ELV040281752 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV040281752</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625231412.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.currproblcancer.2016.11.003</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017003000025.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV040281752</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0147-0272(16)30172-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">150</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">LING</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">77.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Krishnan, Venkatesh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Immunotherapy in ovarian cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">16</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Immunotherapy aims to develop combination approaches that simultaneously augment immunity while preventing local immune suppression. Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for patients with ovarian cancer are inadequate. Advances in immunotherapy offer a promising frontier for treating ovarian tumors. Multiple immunotherapeutic modalities are currently developed and tested in clinical trials. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor–modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Immunotherapy aims to develop combination approaches that simultaneously augment immunity while preventing local immune suppression. Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for patients with ovarian cancer are inadequate. Advances in immunotherapy offer a promising frontier for treating ovarian tumors. Multiple immunotherapeutic modalities are currently developed and tested in clinical trials. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor–modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ovarian cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immunotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Berek, Jonathan S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dorigo, Oliver</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Mosby</subfield><subfield code="a">Bernard, Jonathan Y. ELSEVIER</subfield><subfield code="t">Breastfeeding, Polyunsaturated Fatty Acid Levels in Colostrum and Child Intelligence Quotient at Age 5-6 Years</subfield><subfield code="d">2017</subfield><subfield code="g">Orlando, Fla</subfield><subfield code="w">(DE-627)ELV020620217</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:41</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:48-63</subfield><subfield code="g">extent:16</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.currproblcancer.2016.11.003</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-LING</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">77.00</subfield><subfield code="j">Psychologie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">41</subfield><subfield code="j">2017</subfield><subfield code="e">1</subfield><subfield code="h">48-63</subfield><subfield code="g">16</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Krishnan, Venkatesh |
| spellingShingle |
Krishnan, Venkatesh ddc 610 ddc 150 fid LING bkl 77.00 Elsevier ovarian cancer Elsevier Immunotherapy Immunotherapy in ovarian cancer |
| authorStr |
Krishnan, Venkatesh |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV020620217 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 150 - Psychology |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 150 VZ LING DE-30 fid 77.00 bkl Immunotherapy in ovarian cancer ovarian cancer Elsevier Immunotherapy Elsevier |
| topic |
ddc 610 ddc 150 fid LING bkl 77.00 Elsevier ovarian cancer Elsevier Immunotherapy |
| topic_unstemmed |
ddc 610 ddc 150 fid LING bkl 77.00 Elsevier ovarian cancer Elsevier Immunotherapy |
| topic_browse |
ddc 610 ddc 150 fid LING bkl 77.00 Elsevier ovarian cancer Elsevier Immunotherapy |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
j s b js jsb o d od |
| hierarchy_parent_title |
Breastfeeding, Polyunsaturated Fatty Acid Levels in Colostrum and Child Intelligence Quotient at Age 5-6 Years |
| hierarchy_parent_id |
ELV020620217 |
| dewey-tens |
610 - Medicine & health 150 - Psychology |
| hierarchy_top_title |
Breastfeeding, Polyunsaturated Fatty Acid Levels in Colostrum and Child Intelligence Quotient at Age 5-6 Years |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV020620217 |
| title |
Immunotherapy in ovarian cancer |
| ctrlnum |
(DE-627)ELV040281752 (ELSEVIER)S0147-0272(16)30172-6 |
| title_full |
Immunotherapy in ovarian cancer |
| author_sort |
Krishnan, Venkatesh |
| journal |
Breastfeeding, Polyunsaturated Fatty Acid Levels in Colostrum and Child Intelligence Quotient at Age 5-6 Years |
| journalStr |
Breastfeeding, Polyunsaturated Fatty Acid Levels in Colostrum and Child Intelligence Quotient at Age 5-6 Years |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 100 - Philosophy & psychology |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
48 |
| author_browse |
Krishnan, Venkatesh |
| container_volume |
41 |
| physical |
16 |
| class |
610 610 DE-600 610 VZ 150 VZ LING DE-30 fid 77.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Krishnan, Venkatesh |
| doi_str_mv |
10.1016/j.currproblcancer.2016.11.003 |
| dewey-full |
610 150 |
| title_sort |
immunotherapy in ovarian cancer |
| title_auth |
Immunotherapy in ovarian cancer |
| abstract |
Immunotherapy aims to develop combination approaches that simultaneously augment immunity while preventing local immune suppression. Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for patients with ovarian cancer are inadequate. Advances in immunotherapy offer a promising frontier for treating ovarian tumors. Multiple immunotherapeutic modalities are currently developed and tested in clinical trials. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor–modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery. |
| abstractGer |
Immunotherapy aims to develop combination approaches that simultaneously augment immunity while preventing local immune suppression. Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for patients with ovarian cancer are inadequate. Advances in immunotherapy offer a promising frontier for treating ovarian tumors. Multiple immunotherapeutic modalities are currently developed and tested in clinical trials. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor–modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery. |
| abstract_unstemmed |
Immunotherapy aims to develop combination approaches that simultaneously augment immunity while preventing local immune suppression. Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for patients with ovarian cancer are inadequate. Advances in immunotherapy offer a promising frontier for treating ovarian tumors. Multiple immunotherapeutic modalities are currently developed and tested in clinical trials. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor–modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-LING |
| container_issue |
1 |
| title_short |
Immunotherapy in ovarian cancer |
| url |
https://doi.org/10.1016/j.currproblcancer.2016.11.003 |
| remote_bool |
true |
| author2 |
Berek, Jonathan S. Dorigo, Oliver |
| author2Str |
Berek, Jonathan S. Dorigo, Oliver |
| ppnlink |
ELV020620217 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1016/j.currproblcancer.2016.11.003 |
| up_date |
2024-07-06T17:06:04.323Z |
| _version_ |
1803850155896602624 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV040281752</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625231412.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.currproblcancer.2016.11.003</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017003000025.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV040281752</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0147-0272(16)30172-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">150</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">LING</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">77.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Krishnan, Venkatesh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Immunotherapy in ovarian cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">16</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Immunotherapy aims to develop combination approaches that simultaneously augment immunity while preventing local immune suppression. Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for patients with ovarian cancer are inadequate. Advances in immunotherapy offer a promising frontier for treating ovarian tumors. Multiple immunotherapeutic modalities are currently developed and tested in clinical trials. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor–modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Immunotherapy aims to develop combination approaches that simultaneously augment immunity while preventing local immune suppression. Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for patients with ovarian cancer are inadequate. Advances in immunotherapy offer a promising frontier for treating ovarian tumors. Multiple immunotherapeutic modalities are currently developed and tested in clinical trials. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor–modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ovarian cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immunotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Berek, Jonathan S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dorigo, Oliver</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Mosby</subfield><subfield code="a">Bernard, Jonathan Y. ELSEVIER</subfield><subfield code="t">Breastfeeding, Polyunsaturated Fatty Acid Levels in Colostrum and Child Intelligence Quotient at Age 5-6 Years</subfield><subfield code="d">2017</subfield><subfield code="g">Orlando, Fla</subfield><subfield code="w">(DE-627)ELV020620217</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:41</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:48-63</subfield><subfield code="g">extent:16</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.currproblcancer.2016.11.003</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-LING</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">77.00</subfield><subfield code="j">Psychologie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">41</subfield><subfield code="j">2017</subfield><subfield code="e">1</subfield><subfield code="h">48-63</subfield><subfield code="g">16</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.400667 |